IL4R
Interleukin-4 receptor subunit alpha
Also known as: CD124, IL4RA_HUMAN
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- P24394
- Gene
- IL4R
- Ensembl
- ENSG00000077238
- Chromosome
- 16
- Canonical length
- 825 aa
- Protein class
- Cancer-related genes, CD markers, FDA approved drug targets, Human disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters
- Subcellular location
- Nucleoplasm,Plasma membrane,Centriolar satellite
- Secretome location
- Secreted to blood
OverviewNCBI Gene
This gene encodes the alpha chain of the interleukin-4 receptor, a type I transmembrane protein that can bind interleukin 4 and interleukin 13 to regulate IgE production. The encoded protein also can bind interleukin 4 to promote differentiation of Th2 cells. A soluble form of the encoded protein can be produced by proteolysis of the membrane-bound protein, and this soluble form can inhibit IL4-mediated cell proliferation and IL5 upregulation by T-cells. Allelic variations in this gene have been associated with atopy, a condition that can manifest itself as allergic rhinitis, sinusitus, asthma, or eczema. Polymorphisms in this gene are also associated with resistance to human immunodeficiency virus type-1 infection. Alternate splicing results in multiple transcript variants. [provided by RefSeq, Apr 2012]
Canonical amino-acid sequenceUniProt
825 residues, UniProt reviewed canonical sequence.
>P24394|IL4R
1 MGWLCSGLLF PVSCLVLLQV ASSGNMKVLQ EPTCVSDYMS ISTCEWKMNG PTNCSTELRL
61 LYQLVFLLSE AHTCIPENNG GAGCVCHLLM DDVVSADNYT LDLWAGQQLL WKGSFKPSEH
121 VKPRAPGNLT VHTNVSDTLL LTWSNPYPPD NYLYNHLTYA VNIWSENDPA DFRIYNVTYL
181 EPSLRIAAST LKSGISYRAR VRAWAQCYNT TWSEWSPSTK WHNSYREPFE QHLLLGVSVS
241 CIVILAVCLL CYVSITKIKK EWWDQIPNPA RSRLVAIIIQ DAQGSQWEKR SRGQEPAKCP
301 HWKNCLTKLL PCFLEHNMKR DEDPHKAAKE MPFQGSGKSA WCPVEISKTV LWPESISVVR
361 CVELFEAPVE CEEEEEVEEE KGSFCASPES SRDDFQEGRE GIVARLTESL FLDLLGEENG
421 GFCQQDMGES CLLPPSGSTS AHMPWDEFPS AGPKEAPPWG KEQPLHLEPS PPASPTQSPD
481 NLTCTETPLV IAGNPAYRSF SNSLSQSPCP RELGPDPLLA RHLEEVEPEM PCVPQLSEPT
541 TVPQPEPETW EQILRRNVLQ HGAAAAPVSA PTSGYQEFVH AVEQGGTQAS AVVGLGPPGE
601 AGYKAFSSLL ASSAVSPEKC GFGASSGEEG YKPFQDLIPG CPGDPAPVPV PLFTFGLDRE
661 PPRSPQSSHL PSSSPEHLGL EPGEKVEDMP KPPLPQEQAT DPLVDSLGSG IVYSALTCHL
721 CGHLKQCHGQ EDGGQTPVMA SPCCGCCCGD RSSPPTTPLR APDPSPGGVP LEASLCPASL
781 APSGISEKSK SSSSFHPAPG NAQSSSQTPK IVNFVSVGPT YMRVSLocalizationUniProt · AlphaFold · HPA
Whether an antibody against IL4R can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Cell surface
- Secreted
- No
- Transmembrane segments
- 1
- Mean surface accessibility (rSASA)
- 0.59
- Highest tissue expression
- 114 nTPM
Expression across tissuesHPA
Tissue
- lung: 114 nTPM
- liver: 112 nTPM
- lymph node: 110 nTPM
- bone marrow: 98 nTPM
- colon: 92 nTPM
- spleen: 88 nTPM
Single-cell type
- neutrophils: 758 nCPM
- mast cells: 320 nCPM
- epicardial cells: 277 nCPM
- neutrophil progenitors: 208 nCPM
- b-cells: 152 nCPM
- vascular endothelial cells: 151 nCPM
Immune cell
- naive B-cell: 77 nTPM
- neutrophil: 31 nTPM
- memory B-cell: 25 nTPM
- eosinophil: 13 nTPM
- naive CD4 T-cell: 9.9 nTPM
- NK-cell: 8.4 nTPM
Brain region
- medulla oblongata: 46 nTPM
- thalamus: 39 nTPM
- spinal cord: 39 nTPM
- pons: 35 nTPM
- white matter: 33 nTPM
- amygdala: 33 nTPM
DiseaseUniProt · ClinVar · IEDB · PubMed
Four sources answering four different questions about IL4R.
Disease | ImmuneIEDB
Conditions an epitope on IL4R was assayed in.
- chronic lymphocytic leukemia T cell
ReferencesPubMed · IEDB
Publications for IL4R from three distinct lines of evidence, kept separate because they answer different questions: whether antibodies are directed at the protein, whether a B-cell epitope has been mapped on it, and whether a T-cell epitope has. Each is labelled with its source.
Reference: AutoantibodyPubMed
2 publications
- Prominent Role of Type 2 Immunity in Skin Diseases: Beyond Atopic Dermatitis.
2022 · J Cutan Med Surg · RCR 4.2 · 42 citations - Eosinophilic granulomatosis with polyangiitis developed after dupilumab administration in patients with eosinophilic chronic rhinosinusitis and asthma: a case report.
2023 · BMC Pulm Med · RCR 4.2 · 30 citations
Reference: B cellIEDB
1 publication
- Peptide microarray-based characterization of antibody responses to host proteins after bacille Calmette-Guérin vaccination.
2017 · Int J Infect Dis · RCR 0.7 · 19 citations
Reference: T cellIEDB
1 publication
- HLA ligandome analysis identifies the underlying specificities of spontaneous antileukemia immune responses in chronic lymphocytic leukemia (CLL).
2015 · Proc Natl Acad Sci U S A · RCR 3.6 · 140 citations
Sources: PubMed — antigen-level antibody evidence from a custom retrieval. Records matching a controlled set of autoantibody terms (the MeSH descriptors Autoantibodies and Autoantigens, with title and abstract term variants) were obtained through NCBI E-utilities, and their titles and abstracts parsed for constructions that direct an antibody at a named protein rather than for co-occurrence. Captured names were resolved against UniProt nomenclature and each antigen adjudicated individually against the source text. IEDB — curated epitope assays from the Immune Epitope Database (Vita et al., Nucleic Acids Research 2019). Bibliographic records from PubMed and MeSH, U.S. National Library of Medicine; citation metrics from NIH iCite (Hutchins et al., PLoS Biology 2016). Titles link to PubMed; abstracts are not reproduced here. The NLM does not endorse this analysis.
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 0.83
- gnomAD pLI
- 0
- gnomAD missense Z
- 0.77
- DepMap mean gene effect
- -0.01
- DepMap dependency class
- selective
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- defense response to protozoan
- immune response
- immunoglobulin mediated immune response
- interleukin-4-mediated signaling pathway
- negative regulation of T-helper 1 cell differentiation
- positive regulation of chemokine production
- positive regulation of cold-induced thermogenesis
- positive regulation of immunoglobulin production
- positive regulation of macrophage activation
- positive regulation of mast cell degranulation
- positive regulation of myoblast fusion
- positive regulation of T-helper 2 cell differentiation
- production of molecular mediator involved in inflammatory response
- signal transduction
- T-helper 1 cell differentiation
- T-helper 2 cell differentiation
Molecular functions
- interleukin-4 receptor activity
Cellular components
Protein domainsUniProt · Pfam · InterPro
- Short hematopoietin receptor, family 1, conserved site
- Fibronectin type III
- Immunoglobulin-like fold
- Fibronectin type III superfamily
- Interleukin-4 receptor alpha, N-terminal
- Interleukin-4 receptor alpha chain, N-terminal
KeywordsUniProt
InteractionsUniProt · HPA
Protein binding partners of IL4R in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads IL4R as an antibody target. Whether an autoantibody or antibody against IL4R could matter depends on whether native IL4R is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
IL4R is annotated at the cell surface, where native IL4R is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.
Annotation status
The present source text does not explicitly label IL4R as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...